Very few changes in in analysts’ opinion this week. The biggest story is that, of the few analyst reporting an opinion on Friday for MannKind, none were particularly concerned about the potential fraud issue. Additionally, analysts remain very positive on Orexigen.
Also, I’m surprised that there were no updates on analyst positions for Mela Sciences (MELA) which has an FDA panel on November 18.
Here is an update of analyst activity on stocks with upcoming FDA catalyst dates.
Human Genome Sciences (HGSI) -
11/5 – Lazard maintains buy, price target unchanged at $31.00.
11/4 – RBC Capital Markets maintains outperform, price target unchanged at $38.00.
11/4 – ISI Group maintains hold, price target unchanged at $32.00.
11/3 – JPMorgan maintains overweight, price target unchanged at $38.00.
Orexigen (OREX) -
11/5 – Jefferies maintains buy, price target unchanged at $12.00.
11/4 – Leerink Swann maintains outperform.
11/4 – Canaccord Genuity maintains buy, price target unchanged at $14.00.
11/4 – Cowen maintains outperform.
11/4 – JMP Securities maintains market outperform, price target unchanged at $13.00.
11/4 – Lazard maintains hold.
11/4 – JPMorgan maintains overweight, price target unchanged at $8.00.
11/4 - Rodman & Renshaw maintains market perform.
11/3 – IPOFinancial.com maintains buy.
11/3 – Davenport & Co. maintains nuetral.
Cumberland Pharmaceuticals (CPIX) -
11/5 – Wells Fargo Securities maintains market perform.
MannKind (MNKD) -
11/5 – CRT Capital maintains buy, price target raised to $13.75.
11/5 – Wells Fargo Securities maintains outperform.
11/4 – Oppenheimer & Co. maintains underperform, price target unchanged at $2.00.
11/1 – Robert W. Baird maintains market underperform, price target unchanged at $5.00.
11/1 – Leerink Swann maintains underperform.
11/1 – Rodman & Renshaw maintains outperform, price target unchanged at $18.00.
11/1 – JMP Securities maintains outperform, price target unchanged at $11.00.
Clinical Data (CLDA) -
11/5 – Wedbush maintains outperform, price target unchanged at $28.00.
11/1 – BMO Capital Markets maintains outperform, price target unchanged at $28.00.
11/1 – McNicoll Lewis & Vlak maintains buy, price target unchanged at $37.00.
Depomed (DEPO) -
11/3 – Roth Capital Partners maintains buy, price target unchanged at $7.00.
Protalix (PLX) -
11/3 – Canaccord Genuity maintains buy, price target unchanged at $10.00.
11/2 – Oppenheimer & Co. maintains outperform.
